Repair of the injured spinal cord, a joint approach of basic and clinical research by Buchli, Anita D. et al.
ht
tp
://
do
c.
re
ro
.c
h
 Repair of the Injured Spinal Cord 
 A Joint Approach of Basic and Clinical Research  
 Anita D. Buchli   a     Eric Rouiller   c     Roland Mueller   b     Volker Dietz   b     
Martin E. Schwab   a   
  a   Brain Research Institute, University and ETH Zurich, and  b   Spinal Cord Injury Center, Balgrist University Hospital, 
 Zurich , and  c   Department of Medicine, Unit of Physiology, University of Fribourg,  Fribourg , Switzerland
 
gether basic researchers, clinicians and engineers from 
different academic institutions (Federal Institute of Tech-
nology, University of Zurich and Fribourg, Balgrist Uni-
versity Hospital Zurich) and industry to collaborate on 
distinct aspects of this project resulted in an extremely 
fruitful exchange of ideas and has greatly accelerated the 
progress of the project.
 One of the basic science groups within this project has 
developed regeneration-enhancing treatments for in-
creased restoration of function after spinal cord injury. 
Their validation has now been successful in a preclinical 
setting in mouse, rat and monkey models – a key prereq-
uisite to enter clinical trials. A network of paraplegic cen-
ters in Europe and North America has been created where 
clinical studies can be pursued ensuring comparable di-
agnostic methods, treatment schedules and follow-ups. 
Phase I clinical trials with an anti-Nogo-A antibody treat-
ment of acute para- and tetraplegic patients have recently 
been initiated.
 Basic Research and Proof of Principle of 
Regeneration-Enhancing Anti-Nogo Antibody 
Treatment in Rodent Models 
 Several lines of evidence suggested the presence of spe-
cific inhibitory factors responsible for the nonconducive 
properties of central nervous system (CNS) tissue for ax-
onal regeneration in adult vertebrates. CNS white matter 
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 Abstract 
 The myelin protein Nogo-A is a potent inhibitor of neurite 
outgrowth in the central nervous system, thus contributing 
to the incapacity of fiber tracts in the adult spinal cord to re-
generate after injury. In this review we report on a joint ap-
proach of different research groups to develop a therapy ap-
plying anti-Nogo-A antibodies to the injured spinal cord. 
While basic researchers took the initiative to provide means 
of neutralizing the inhibitory effect of Nogo-A and demon-
strated enhanced fiber growth, regeneration and functional 
recovery both in rodent and primate models, clinical groups 
and rehabilitation engineers have sought to translate this 
novel strategy into a clinical setting. 
 Introduction 
 The aim of the project ‘Spinal Cord Repair’ of the 
NCCR ‘Neural Plasticity and Repair’ initiated by the 
Swiss National Science Foundation in 2001 is to develop 
novel treatments for spinal cord injury and implement 
these into a clinical setting. The challenge to bring to-
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contains myelin-associated neurite growth inhibitors 
such as Nogo-A that seem to play a crucial role in prevent-
ing regeneration of lesioned axons in adult animals  [1, 2] . 
The same inhibitory myelin proteins probably also in-
hibit structural plasticity in higher vertebrates  [2, 3] . Dif-
ferent antibodies that neutralize the inhibitory activity of 
Nogo-A have been developed and their regeneration-en-
hancing effect for CNS axons was tested both in vitro and 
in vivo. 
 In vivo studies were performed with adult rats le-
sioned at spinal cord thoracic level T8, which received 
anti-Nogo-A antibodies through the cerebrospinal flu-
id. In Nogo-A antibody-treated animals but not in con-
trol antibody-infused animals, regenerating corticospi-
nal (CS) tract fibers were seen growing down the spinal 
cord ( fig. 1 A). These fibers exceeded a length of 8 mm 
and arborized profusely into the gray matter. In addi-
tion to regenerative growth of lesioned axons, sprouting 
and compensatory fiber growth was observed from 
spared, unlesioned fiber systems  [3–6] . This suggested 
that both these phenomena – regeneration and struc-
tural plasticity – probably contribute to the often high 
degree of functional recovery observed in these ani-
mals. The behavioral results summarized below also 
suggest that the fibers growing and regenerating in the 
adult CNS tissue seem to be able to recognize function-
ally meaningful targets and to form new functional cir-
cuits.
 In spinal cord-injured (SCI) adult rats, intrathecal in-
fusion of anti-Nogo-A antibodies resulted in impressive 
improvements of functional recovery in particular of lo-
comotor functions like swimming, running, or crossing 
horizontal ladders or beams ( fig. 1 B, C)  [4, 6, 7] . In these 
studies malfunctions like pain or spasticity – both pos-
sible indicators for misled axons or erroneous connec-
tions – were consistently absent, suggesting that the new 
connections and circuits are formed with high specific-
ity. Functional magnetic resonance imaging (functional 
MRI) was applied to study the cortical representation of 
forelimbs and hind limbs and their responsiveness to 
peripheral sensory stimulation after SCI. In contrast to 
control antibody-treated animals, SCI rats treated with 
anti-Nogo-A antibodies revealed significant cortical re-
sponses in functional MRI after hind paw stimulation, 
suggesting restitution of afferent spinocerebral path-
ways  [6] .
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Fig. 1. Long-distance and functional regeneration after spinal 
cord injury in rats ( A ), and functional recovery in anti-Nogo-A 
antibody-treated rats after spinal cord injury ( B ,  C ).  A Regenera-
tion in the spinal cord: camera lucida drawing of sagittal sections 
of the lower thoracic spinal cord including the lesion site (left). 
Neutralization of Nogo-A leads to enhanced sprouting rostral to 
the lesion (left) and to fibers crossing the lesion on remaining tis-
sue bridges into the caudal spinal cord and growing down the 
spinal cord over long distances (right to the lesion site).  B Rat bal-
ancing over a narrow beam.  C Anti-Nogo-A-treated animals (an-
tibodies 11C7, 7B12) show improved performance in the swim test 
compared with the control IgG antibody-treated SCI rats. With 
permission from  Annals of Neurology . * p ! 0.01; ** p ! 0.001.
2
ht
tp
://
do
c.
re
ro
.c
h
 In the future, the impact of rehabilitative training on 
regeneration and plasticity in the spinal cord and brain 
(including the neocortex), and on functional recovery 
will be studied in adult rats. For this, a combination of 
specific lesion models with anti-Nogo-A antibody treat-
ment, different tracing techniques and physical training 
are envisaged. In addition to behavioral analysis, these 
experiments allow us to study effects on fiber growth and 
anatomical plasticity.
 Very little information is available on the distribution 
of therapeutic antibodies infused into the cerebrospinal 
fluid. We therefore studied the distribution and tissue 
penetration of antibodies after 7–14 days of intrathecal 
infusion in adult rats and monkeys  [8] . Anti-Nogo-A an-
tibodies reached the brain and whole spinal cord and 
penetrated deep into the parenchyma where they bound 
to oligodendrocytes and nerve cells. They were subse-
quently internalized together with the endogenous cell 
surface Nogo-A, leading to a down-regulation of CNS 
Nogo-A levels.
 Nogo-A knockout mice, which can serve as a useful 
proof of principle for the inhibitory effect of Nogo-A on 
regeneration, were successfully generated. CS tract re-
generation was enhanced following injury in the absence 
of Nogo-A  [9] . To exclude a role of background genes, 
these Nogo-A knockout mice were successfully back-
crossed into two different commonly used mouse strains 
(unpublished data). After spinal cord lesion, Nogo-A-de-
ficient mice of both strains showed enhanced regenera-
tive sprouting and long-distance regeneration as com-
pared to wild-type mice of the same background. Sur-
prisingly, however, one of the strains (SV129) displayed 
significantly higher numbers of regenerating fibers than 
the Nogo-A knockouts of the other strain (C57Bl/6). 
These results confirm that Nogo-A is an important en-
dogenous inhibitor of axonal regeneration in the adult 
spinal cord; they also demonstrate that the effects of 
Nogo-A deletion can be modified by mouse strain-spe-
cific genes.
 The reaction of neurons and CNS tissue to anti-Nogo-
A antibody treatment on the one hand and the conse-
quences of loss of Nogo-A expression in knockout ani-
mals on the other hand are being studied at the molecu-
lar level by a functional genomics approach. The aim of 
these experiments is to identify molecules associated 
with axon (re-)growth, to gain insight into signaling 
mechanisms involved in regeneration processes, and to 
find cues involved in neuronal circuit formation in the 
adult CNS.
 Enhancement of Functional Recovery and Axonal 
Regrowth in Monkeys Treated with Anti-Nogo-A 
Antibodies after Lesion of the Cervical Spinal Cord 
 In order to translate the anti-Nogo-A antibody strat-
egy from rodents to subhuman primates, monkeys have 
been subjected to SCI. Since the general organization of 
the CS system is considerably different between rodents 
and primates, a proof of principle in monkeys represents 
a crucial step before clinical application to human pa-
tients. Furthermore, the monkey model is more appropri-
ate than rodents to test whether anti-Nogo-A antibody 
treatment does not generate undesired secondary effects, 
such as chronic pain.
 Twelve adult Macaque monkeys ( Macaca fascicularis 
 or Macaca mulatta ; 3.5–5 kg; 3–4 years old) were trained 
to perform a manual dexterity task ( fig. 2 B). The mon-
keys retrieved food pellets from 50 wells using the oppo-
sition of thumb and index, i.e. the precision grip. The 
number of pellets retrieved within 30 s was determined 
( fig. 2 A). After about 2 months a subhemisection was 
performed unilaterally at the C7/C8 level  [10–12] . The le-
sion completely interrupted the main CS component in 
the dorsolateral funiculus ( fig. 2 C, arrow). Immediately 
after the lesion, 6 monkeys were treated with an anti-
Nogo-A antibody delivered intrathecally near the lesion 
site for 4 weeks from an osmotic pump. An inactive con-
trol antibody was infused in the other 6 monkeys. Behav-
ioral testing was continued for 2–3 months postlesion in 
order to compare the extent and time course of function-
al recovery between the two groups of monkeys. Finally, 
an anterograde neuroanatomical tracer (biotinylated 
dextran amine, BDA) was injected in the primary motor 
cortex contralateral to the cervical lesion, in order to 
trace the CS tract and its regenerated fibers.
 In all monkeys, the hand homolateral to the lesion was 
dramatically impaired immediately after the lesion and 
then, over a period of a few weeks, progressive partial re-
covery of manual dexterity took place. The 2 monkeys 
shown in  figure 2 A exhibited a comparable cervical cord 
lesion, but the anti-Nogo-A antibody-treated monkey 
(red) recovered faster and much more completely than 
the control antibody-treated animal (blue). Overall, con-
trol antibody-treated monkeys exhibited a recovery of 
manual dexterity that was inversely correlated to the le-
sion extent ( fig. 2 D, blue circles), whereas anti-Nogo-A 
antibody-treated monkeys recovered faster and almost 
completely, irrespective of lesion size ( fig. 2 D, red 
squares). In addition to the above-mentioned ability to 
grasp pieces of food with the precision grip, a better re-
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 Fig. 2.  A Typical manual dexterity score (successful food pellet 
retrieval) derived from daily sessions of precision grip task (Mod-
ified Brinkman Board) for 2 monkeys: control antibody-treated 
(blue) and anti-Nogo-A antibody-treated (red). The dexterity 
score is high before the lesion, falls to a very low level after the 
spinal cord injury, and recovers to about 30–40% in the control, 
but to 100% of the original performance in the anti-Nogo-A an-
tibody-treated animal. The insets (top) show the extent of the le-
sion on a cross section of the cervical spinal cord, for the control 
antibody- (blue) and anti-Nogo-A antibody-treated monkeys 
(red). The lesion completely interrupted the dorsolateral funicu-
lus and covered a comparable extent of the hemicord in the 2 mon-
keys.  B View of the left hand of a monkey while performing the 
grasping of a pellet from a well in the Brinkman Board test. 
 C  Frontal section of the cervical cord in an intact monkey showing 
the distribution of the corticospinal (CS) axons as a result of BDA 
injection in the right motor cortex. Each labeled CS axon is rep-
resented by a small dot. The arrow points to the main CS compo-
nent, the crossed dorsolateral funiculus, which was destroyed by 
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covery in anti-Nogo-A antibody-treated monkeys was 
also observed for behavioral tasks testing other motor pa-
rameters, such as force and ballistic grasping or catching 
of moving objects.
 A detailed anatomical investigation of the transected 
CS tract showed that application of antibodies neutral-
izing Nogo-A led to a significant increase in BDA-la-
beled CS axonal arbors and CS axonal swellings caudal 
to the lesion, as compared to control antibody-treated 
monkeys. Rostral to the lesion, the anti-Nogo-A anti-
body treatment induced a reduction of the incidence of 
axonal retraction bulbs, attenuation of CS axonal die-
back and increased sprouting of CS fibers. Very few CS 
axons truly regenerated by recrossing the lesion; in-
stead, anti-Nogo-A antibody treatment enhanced col-
lateral sprouting, which gave rise to BDA-labeled axons 
seen growing around the lesion medially in the gray 
matter. The fibers then elongated into the denervated 
gray matter territory caudal to the lesion. The presence 
of CS axonal arbors caudal to the lesion correlated with 
the level of functional recovery, suggesting that the re-
generative sprouting of the CS tract contributed to the 
recovery of manual dexterity. Very importantly, the 
monkeys treated for 4 weeks with the anti-Nogo-A an-
tibody did not show any sign of chronic pain or change 
of general behavior, neither with their mates within the 
colony in the animal room nor with respect to the ex-
perimenters. The monkeys were in good health as indi-
cated by a stable body weight postlesion during the infu-
sion of the antibody. This study in monkeys extended 
the findings with anti-Nogo-A antibody therapy in ro-
dents to primates, paving the way for clinical applica-
tion to human SCI patients.
 Clinical Issues 
 To document the changes at the neurological and 
functional level after human spinal cord injury and there-
fore provide a historical control group for future clinical 
trials, a European multicenter study (EM-SCI) was initi-
ated in 2001  [13] . In this study, standardized assessments 
covering neurological, functional and electrophysiologi-
cal aspects are done at defined time points after the in-
jury. Additional protocols monitoring pain, bladder func-
tion and acute care treatment will be included in the near 
future. New tests for voluntary function of the legs cover-
ing the whole rehabilitation period and neurophysiologi-
cal methods for the assessment of impaired function of 
specific spinal pathways are underway. Analysis of the 
currently more than 700 patient data allows a better strat-
ification of patient subgroups and a more precise predic-
tion of outcome. This will help recognize even small im-
provements in the recovery of functions and to monitor 
any significant effect of a new treatment.
 If such a new treatment could produce axonal regen-
eration in the lesioned human spinal cord the spinal cir-
cuits below the lesion should be preserved. This is espe-
cially true for clinically complete SCI patients where only 
regeneration approaches may succeed. Recently, signs of 
decreased neuronal function in the lower spinal cord 
were found in chronic complete SCI patients; they were 
restricted to the specific motor behaviors affected by the 
injury, e.g. locomotion  [14] . The affected spinal neuronal 
circuits seem to be at least partially different from spinal 
reflex circuits as the latter do not show such decreased 
function  [15] . Possible preventive effects of early motor 
training combined with pharmacological interventions 
(e.g.  L -dopa) are being evaluated. Earlier results have al-
ready shown that loading and hip position afferents are 
essential to stimulate the spinal neuronal circuits in-
volved in locomotion  [16] .
 Long-term training studies with chronic incomplete 
SCI patients showed that these patients profit from an 
assisted locomotor training for their mobility  [17] . Ro-
botic devices for gait (Lokomat  ,  fig. 3 ) and arm func-
tion (ARMin) with novel training and feedback strate-
gies have been introduced and are expected to enhance 
the positive output of assisted training in patients with 
SCI  [18, 19] .
the lesion in the present study.  D For 9 monkeys, the plot shows 
the relationship between the extent of the spinal cord lesion (ab-
scissa) and the degree of functional recovery (ordinate). A func-
tional recovery of 100% means that the postlesion score came 
back to the level of the prelesion score. The extent of the lesion was 
expressed in percent of the zone in the white matter of the hemi-
cord including the dorsolateral funiculus (main CS tract compo-
nent) and the rubrospinal (RS) tract. In control antibody-treated 
monkeys ( I ), the functional recovery was inversely correlated to 
the lesion extent (r = –0.82); in contrast, all the anti-Nogo-A an-
tibody-treated animals ( + ) reached 90–100% of recovery. 
 Fig. 3. Assisted treadmill training within a driven gait orthosis 
(Lokomat). Subjects are suspended in a harness. Body weight sup-
port as well as treadmill speed can be adapted to the patient’s abil-
ity. The orthosis is equipped with sensors to provide feedback of 
the subject’s performance to the patient and the therapist. Differ-
ent patient-cooperative control strategies are implemented to en-
hance training success (picture courtesy of Hocoma AG, 
Volketswil, Switzerland). 
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 New insights into the integrity of spinal circuits will 
be provided by studies applying high-resolution MRI 
techniques (functional MRI, diffusion tensor imaging) to 
the injured spinal cord  [20] . Although very challenging, 
this approach holds great promise for the assessment of 
spared tract anatomy, residual spinal cord function, and 
the recovery of spinal pathways in a noninvasive man-
ner.
 Electrophysiological recordings at the level of the le-
sion have been shown to serve as an objective diagnostic 
tool to assess the integrity of autonomic afferent nerve 
pathways and to distinguish between central and periph-
eral lesions  [21] . In SCI patients, synchronized activation 
and inactivation of the autonomic and somatic pathways 
was shown to be necessary for appropriate urine storage 
and coordinated bladder voiding. The chronology of 
bladder dysfunction has been assessed, providing the ba-
sis for conditional neuromodulation in patients with SCI 
 [22] . This is a promising treatment for bladder dysfunc-
tion, which is a more confining issue for a majority of SCI 
patients than the walking impairment.
 In conclusion, the concerted efforts of basic scientists 
working with rat and monkey models of SCI as well as 
cell biological and molecular biological tools on the one 
hand, and clinical researchers including neurorehabilita-
tion specialists and engineers on the other hand in the 
NCCR project ‘Spinal Cord Repair’ have led to the full 
translation of basic science findings into a clinical trial: 
in close collaboration with Novartis Pharma in Basel, a 
phase I clinical trial in humans with anti-Nogo-A anti-
bodies was started in the spring of 2006.
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